11-03-2025
Singapore's SGI announces JV to expedite financing for clinical trials
Singapore-based SPRIM Global Investments (SGI) and One Investment Management (OneIM) have announced a $300m joint venture (JV) to expedite financing for clinical trials.
This alliance is set to broaden SGI's TrialCap platform, which provides specialised funding solutions for clinical trials ranging from Phase I through Phase III.
TrialCap's two decades of industry 'expertise' is set to offer flexible and financial backing to medtech and biotech firms. This is expected to assist these companies in progressing their therapies and bringing treatments to market sooner.
SGI managing partner and co-founder Michael Shleifer said: 'Our mission is to remove financial barriers that hinder biotech and medtech companies from focusing on research and development.
'Through this strategic partnership with OneIM, we are significantly expanding our ability to provide critical financing solutions that drive innovation in life sciences.'
SGI, established in 2008, is a private investment firm with a focus on clinical-stage life sciences and pharmaceutical services.
Its investment model is designed to offer 'agile' financing to biotech companies globally, thereby backing the trial progression and the development of transformative treatments.
OneIM is an alternative investment manager that invests across various asset classes and industries and its team operates from offices in London, Abu Dhabi, Tokyo and New York.
Founded in 2022, it manages assets worth approximately $7bn.
OneIM partner Matt Ross said: 'We see tremendous opportunities in the life sciences sector and are delighted to collaborate with SGI, a firm that has a proven track record, deep connectivity across the healthcare ecosystem, and a strong pipeline of opportunities.
'We look forward to accelerating the growth of this platform alongside Michael and the team.'
"Singapore's SGI announces JV to expedite financing for clinical trials" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
